Phase 1 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 to 80 years old
- People who can read and understand Danish
- People who have been diagnosed with uveal melanoma (a type of eye cancer) that has not yet been treated, is localised to the eye, and is classified as high risk (T3 or T4 stage), with surgery to remove the eye already planned and tissue sampling possible
- People who are generally well enough to carry out daily activities with little or no limitation (confirmed by a doctor using a standard health scale)
- People whose blood test results at screening meet specific minimum requirements for liver function, kidney function, red blood cells, white blood cells, and platelets (confirm with trial site for exact values)
- People who have given written consent after receiving information about the study
- People who are willing to attend all planned treatments and follow-up appointments
- Women who could become pregnant must have a negative pregnancy test at screening and must use a highly effective form of contraception from screening until 6 months after treatment ends, and must agree not to donate, store, or bank eggs during this time
- Men whose partner could become pregnant must use a condom from screening until 6 months after treatment, ensure their partner also uses a highly effective contraceptive method, and agree not to donate, store, or bank sperm during this time
Who may not be able to join:
- People with a history of other cancers, unless they have had no signs of that cancer for at least 2 years after treatment (some exceptions apply for certain treated skin cancers and some breast conditions — confirm with trial site)
- People who have taken high-dose steroid medications or other immune-suppressing drugs within the 3 weeks before screening
- People with any condition that could affect their ability to safely follow the study requirements, including certain mental health conditions or substance use disorders
- People who are currently pregnant or breastfeeding
- People who have an active infection that requires treatment with medication
- People with serious medical conditions such as severe asthma, severe lung disease, uncontrolled heart disease, or uncontrolled diabetes (as assessed by the study doctor)
- People who are currently taking part in another experimental drug trial
- People with a significant active autoimmune disease (a condition where the immune system attacks the body)
- People who have previously had a severe allergic or life-threatening allergic reaction
- People with a known allergy to any of the active ingredients or other components of the trial medications
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 004538683868
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs); Proportion of patients who complete the treatment regimen
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.